Entering text into the input field will update the search result below

Teladoc: Scary Times

May 01, 2022 8:12 AM ETTeladoc Health, Inc. (TDOC)70 Comments
On the Pulse profile picture
On the Pulse


  • Teladoc Health’s stock plunged after earnings release.
  • Slashed 2022 guidance and big impairment charge indicate business problems.
  • The valuation is still too high.

Patient receiving advice on laptop from physical therapist

10'000 Hours/DigitalVision via Getty Images

The stock price of Teladoc Health Inc. (NYSE:TDOC) is collapsing like a house of cards, owing to slowing sales growth and a massive impairment charge related to an ill-timed acquisition.

Teladoc Health's stock price dropped

TDOC Share Price

TDOC Share Price (Finviz)

Teladoc Revenue And Membership Overview

Revenue And Membership Overview (Teladoc Health)

Teladoc 2022 Guidance

Guidance For 2022 (Teladoc Health)


PS Ratio Chart (YCharts)

This article was written by

On the Pulse profile picture
A financial researcher and avid investor with a keen eye for innovation and disruption, as well as growth buy-outs and value stocks. Keeping an eye on the pace of high tech and early growth companies, I write about current events and the biggest news surrounding the industry, and strive to provide readers with ample research and investment opportunities.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.